Clinical trials for Sarcoma and GIST

71 currently recruiting clinical trials
Phase 1 Sarcoma and GIST #NCT03715933 #2023-508139-29-00
Cohorte sarcome d'Ewing
Bone sarcoma Ewing tumor Locally Advanced Metastatic 1 2
2 recruiting sites
Inhibrx Biosciences, Inc
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT07094204 #2025-522082-29-00
Escalade de dose monothérapie
Locally Advanced Metastatic Metastatic Castration-resistant Other KRAS KRAS G12C KRAS G12D KRAS non G12C 1 2 3 or more
Systemic Treatment-Naive
4 recruiting sites
Astellas Pharma Développement mondial, Inc.
Phase 1 Breast cancer Prostate cancer Kidney cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT07094204 #2025-522082-29-00
Cohorte extension de dose autres tumeurs
Locally Advanced Metastatic Other KRAS KRAS G12C KRAS G12D KRAS non G12C 1 2 3 or more
Systemic Treatment-Naive
4 recruiting sites
Astellas Pharma Développement mondial, Inc.
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT06026410
Bras 1 (Tumeurs solides avancées avec altération du gène RAS)
Locally Advanced Metastatic Other KRAS HRAS KRAS G12C KRAS G12D KRAS non G12C NRAS 1 2 3 or more
Systemic Treatment-Naive
3 recruiting sites
Kura Oncologie, Inc.
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT06179160 #2023-507091-47-00
Locally Advanced Metastatic KRAS G12D 1 2 3 or more
Systemic Treatment-Naive
3 recruiting sites
Incyte Corporation
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT07094113
Parties 1, 2 et 3a
Locally Advanced Metastatic Other KRAS KRAS G12C KRAS G12D KRAS non G12C 1 2 3 or more
Systemic Treatment-Naive
2 recruiting sites
Amgen
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT06781983
Locally Advanced Metastatic Other mutation 1 2 3 or more
Systemic Treatment-Naive
2 recruiting sites
Innate Pharma
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer #NCT06619587
Locally Advanced Metastatic Metastatic Castration-resistant KRAS G12D 1 2 3 or more
Systemic Treatment-Naive
3 recruiting sites
Genentech, Inc
Phase 1 Stomach and esophageal cancer Sarcoma and GIST #NCT05489237 #2024-514930-19-00
Cohorte 4
GIST Gastrointestinal stromal tumor Locally Advanced Metastatic KIT PDGFRA 2 3 or more Targeted therapy
Systemic Treatment-Naive
4 recruiting sites
IDRx Inc. - A GSK Company
Phase 1 Stomach and esophageal cancer Sarcoma and GIST #NCT05489237 #2024-514930-19-00
Escalade de dose (Phase I)
GIST Gastrointestinal stromal tumor Locally Advanced Metastatic KIT PDGFRA 1 2 3 or more Targeted therapy
Systemic Treatment-Naive
4 recruiting sites
IDRx Inc. - A GSK Company